For the treatment of chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors in adult patients.
For the treatment of accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated in adult patients.
For the treatment of T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL in adult patients.
